July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Neuroprotective Effects of Oroxylin A in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy
Author Affiliations & Notes
  • Shun-Ping Huang
    Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan
    Opthalmology, Taichung Tzu Chi Hospital, Taichung, Taiwan
  • Jia-Ying Chien
    Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan
  • Kishan Kapupara
    Institute of eye research , Tzu Chi general hospital, Hualien, Taiwan
  • Yu-Yau Chou
    Molecular Biology and Human Genetics, Tzu Chi University, Hualien, Taiwan
  • Rong-Kung Tsai
    Institute of eye research , Tzu Chi general hospital, Hualien, Taiwan
  • Footnotes
    Commercial Relationships   Shun-Ping Huang, None; Jia-Ying Chien, None; Kishan Kapupara, None; Yu-Yau Chou, None; Rong-Kung Tsai, None
  • Footnotes
    Support  MOST Grant 105-2628-B-320-002-MY3
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2499. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shun-Ping Huang, Jia-Ying Chien, Kishan Kapupara, Yu-Yau Chou, Rong-Kung Tsai; Neuroprotective Effects of Oroxylin A in a Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2499.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study is to evaluate the effect of Oroxylin A on ischemic injury and its molecular mechanims in a rodent model of anterios ischemic optic neuropathy (rAION)

Methods : AION injuction was achieved using laser-coupled photoactivation of optic disc after intraveounsly injection of rose Bengal through tail vein. The male Wistar rats were divided into three experimental groups: (1) sham, (2) AION induction and subcutaneously (SC) injected with PBS, (3) AION induction and SC injected with oroxylin A (15mg/Kg in 0.2ml PBS). Animals were sacrificed at different time post infarct. Evaluation methos include optic coherence tomography (OCT) profile of retinal nerve fiber layer (RNFL) and optic nerve head (ONH), TUENL assay and retrograde labeling fluorogold of retinal ganglion cells (RGCs), immunohistochemical studies of ED1 in ON. Western blot analysis for pro-surviving signaling. Visual function evaluated by flah visual evoked potential (FVEP).

Results : Oroxlyin A treatment signifincaly reduced optic nerve edema in the acute phase of rAION. The RGC survival were significantly improved in AION induction with oroxylin A-treated rats compared with those of AION induction with PBS-treated rats (70% vs 45% survival in the central and 75% vs 40% in mid-peripheral retina). For FVEP assessment, oroxylin A treatment significantly restored the visual function after AION induction. Furthermore, less ED1 positive cells were accumulated in oroxylin A-treated ON indicate the anti-inflammatory effect of oroxylin A at the ON after infarct.

Conclusions : These data indicate that the protective effects of oroxylin A on RGC against ischemic injury may be related to its anti-apoptotic and anti-inflammatory effects. Our finding suggest oroxylin A may be a potential approach for treatment of ischemic optic neuropathies.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×